# orforglipron Type: Product Source: GetYourBrief — https://getyourbrief.com/entity/orforglipron Canonical HTML page: https://getyourbrief.com/entity/orforglipron ## Timeline - **2026-04-14**: JPM Q1 Earnings Report — JPMorgan Chase reports first-quarter financial results amidst regulatory and legal scrutiny. - **2026-04-14**: JPM Earnings — JPMorgan Chase reports Q1 results amid regulatory and legal headwinds. - **2026-04-10**: FDA Orforglipron Decision — Expected regulatory ruling on Eli Lilly's oral GLP-1 candidate for weight loss. - **2026-04-10**: FDA Decision Date — Expected regulatory ruling on orforglipron oral weight loss drug. - **2023**: Zepbound Approval — FDA expands tirzepatide approval to include chronic weight management. - **2022**: Mounjaro Launch — Tirzepatide enters the market for Type 2 Diabetes treatment. ## Recent coverage (7 stories, network-wide) ### Eli Lilly Faces Critical April 10 FDA Decision on Oral Weight Loss Candidate 2026-03-23 00:14:59 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 5 Eli Lilly (LLY) is approaching a pivotal April 10 regulatory milestone for orforglipron, its experimental oral GLP-1 receptor agonist, as it seeks to expand its $11 billion weight-loss portfolio. While the broader market faces volatility from the banking sector's upcoming earnings on April 14, the biotech industry is laser-focused on the potential shift from injectable to oral metabolic therapies. Full story: https://getbiobrief.com/story/eli-lilly-orforglipron-fda-decision-april-catalyst ### April Catalysts: Eli Lilly’s Oral GLP-1 Decision and JPM Earnings Outlook 2026-03-23 00:14:25 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 5 Investors are monitoring two critical mid-April deadlines: the FDA's decision on Eli Lilly's oral weight-loss drug, orforglipron, and JPMorgan Chase's first-quarter earnings report. These events serve as key indicators for the pharmaceutical sector's obesity market expansion and the banking sector's regulatory resilience. Full story: https://gethealthbrief.com/story/eli-lilly-jpmorgan-april-catalysts-analysis ### AI-Driven Growth: Top Stock Picks for the 2026 Machine Learning Expansion 2026-03-04 04:14:08 · Sector: ai · Sentiment: Positive · Impact: 6/10 · Sources: 2 As the AI sector matures in 2026, investors are pivoting toward companies that successfully integrate generative AI and machine learning into specialized verticals like healthcare and voice automation. Key players including Eli Lilly and SoundHound AI are demonstrating how AI-powered drug discovery and conversational interfaces are translating into significant revenue growth and market leadership. Full story: https://getaibrief.com/story/ai-growth-stocks-2026-analysis ### Growth Stock Outlook 2026: AI, Biotech, and Infrastructure Lead H1 Picks 2026-03-04 04:12:31 · Sector: startups · Sentiment: Positive · Impact: 6/10 · Sources: 2 As market volatility persists in early 2026, analysts are pivoting toward high-conviction growth plays in healthcare AI and specialized compute infrastructure. Key picks include Eli Lilly's pharmaceutical dominance and Nebius's explosive ARR projections, signaling a shift toward companies with proven revenue scaling. Full story: https://getstartupbrief.com/story/growth-stock-outlook-2026-ai-biotech-infrastructure ### Growth Stock Outlook 2026: Pharma Giants and AI Disruptors Lead Market 2026-03-04 04:11:57 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 2 As equity markets navigate 2026 volatility, analysts are highlighting a mix of established healthcare leaders and emerging AI infrastructure plays as top growth opportunities. Eli Lilly’s dominance in the obesity market and Nebius’s projected $7 billion revenue surge represent the diverse strategies for capturing alpha in the current cycle. Full story: https://getfinancebrief.com/story/growth-stocks-outlook-h1-2026 ### Eli Lilly and Veeva Lead 2026 Growth Outlook Amid AI-Driven Pharma Shift 2026-03-04 04:11:43 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2 As market volatility persists in early 2026, Eli Lilly and Veeva Systems emerge as top growth picks driven by the obesity drug boom and AI integration. With Eli Lilly's tirzepatide securing its spot as the world's top-selling drug and new oral GLP-1s on the horizon, the pharmaceutical landscape is shifting toward tech-heavy, high-margin innovation. Full story: https://getbiobrief.com/story/eli-lilly-veeva-2026-growth-outlook ### Pharma Giants and AI Disruptors: Top Healthcare Growth Stocks for 2026 2026-03-04 04:09:39 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2 Eli Lilly and Veeva Systems emerge as dominant healthcare growth leaders for 2026, driven by the GLP-1 weight-loss revolution and cloud-based life sciences infrastructure. Meanwhile, SoundHound AI is positioning itself to disrupt medical administrative costs through generative voice AI and automated customer service solutions. Full story: https://gethealthbrief.com/story/healthcare-growth-stocks-2026-analysis --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.